Alpha Scan Companion Report

Date: 2026-04-29 | Depth: scan | Agent: intel-alpha

Sector News Firehose Results

1. Photonics and Optical Computing -- HOT

Fresh catalysts (last 7 days):

• LITE: JPMorgan PT raised to $950, Northland PT $1,000. Stock at ATH, up 28% in April. NVIDIA $2B investment. New NC manufacturing facility announced. Q1 revenue ~$808M (+90% YoY).
• COHR: TD Cowen initiates Buy/$330 PT. Analysts upgrade on industrial laser recovery. NVIDIA $2B investment. Trading at $304 (near ATH $365).
• AAOI: $71M 800G order from hyperscaler, total $124M since mid-March. 350% laser capacity expansion by 2027. Houston facility scaling to 900K sqft.
• TSEM: 400 Gbps/lane SiPh demo with Coherent (March). Axiro SiGe radar IC ramp. Record revenue trajectory on SiPh + RF demand.
• AEHR: Record $41M production order from hyperscale AI customer. SiPh customer win (+23%). H2 bookings >$92M.
• AXTI: $632.5M offering closed to fund InP substrate expansion at Tongmei. Stock up ~6,000% in 1 year. InP is THE bottleneck substrate.
• CRDO: $750M DustPhotonics acquisition for optical vertical integration. Insider selling concerns. Zacks downgrade to Hold.
• POET: -47% on Marvell order cancellation (confidentiality breach). Execution risk elevated. Core tech still valid.

Assessment: SiPh supercycle Day 19, structural re-rate confirmed. NVIDIA $4B bet validates theme. InP substrate shortage (70% supply gap) is the binding constraint. AXTI is the bottleneck play but valuation stretched after $632M raise.

2. Graphene Applications -- MONITOR

• Adisyn (ASX:AI1): Low-temperature ALD graphene on semiconductor-grade wafers (April 20). Stock responding positively.
• Premier Graphene: First military contract from Mexico defense ministry (April 24).
• Paragraf: $55M Series C for wafer-scale graphene electronics.
• No liquid US-listed pure-play with fresh catalyst. Skip for now.

3. Nanotechnology in Semiconductors -- SKIP

• Purdue/Dassault MOU for virtual twin semiconductor processing.
• Chiral (private) raised EUR10M seed for nanomaterial integration.
• No actionable public equity with fresh catalyst. Skip: no public play with near-term catalyst.

4. Quantum Computing -- WATCH

• Google Quantum AI: 20x reduction in resources to crack ECDSA-256.
• Cloudflare accelerating post-quantum security to 2029.
• Sygaldry raises $139M for quantum-accelerated AI servers.
• INFQ at $12.62 (near 200MA $12.06) -- no fresh company-specific catalyst in last 7 days.
• IBM "decisive year" but no public pure-play with immediate catalyst.
• Skip: INFQ has no fresh catalyst in last 7 days; quantum still pre-revenue for most players.

5. Advanced Packaging (Chiplets, 3D Stacking) -- HOT

• Samsung 3.3D packaging mass production Q2 2026 (22% cost reduction vs silicon interposer).
• TSMC monthly capacity doubling to 130K wafers by end-2026.
• AMKR: Record Q1 revenue $1.68B (+27% YoY), EPS $0.33 beat $0.22 est by 50%. CPU advanced packaging mass production H2 2026. Stock at $71.36 (near ATH $79). Analyst consensus is Hold at $54.68 avg PT -- significant lag behind stock.
• Cadence/Samsung chiplet ecosystem on SF5A process.
• UCIe 3.0 standard maturing.

6. Nuclear Energy (Fission, Fusion, SMRs) -- HOT

Fission/SMR:

• OKLO: +26% last week on DOE loan confirmation, HSBC Buy/$96 PT, NVIDIA/LANL partnership. At $69 vs 200MA $86 -- still below 200MA despite rally.
• NuScale (SMR): DOE loan support catalyst, +20% last week. But -70% over 6 months, securities fraud class action pending. Legal risk elevated.
• DOE confirms first 5-10 new reactors will get government loans.
• US Space Nuclear Power Initiative (reactors in orbit by 2028, moon by 2030).

Fusion (MAJOR CATALYST):

• CFS files to connect 400MW fusion plant to PJM grid (April 28) -- FIRST EVER fusion grid filing.
• CFS SPARC magnet ring completion summer 2026, first plasma 2027.
• Google and Eni power purchase agreements already signed.
• CFS is PRIVATE -- no direct equity play. Derivative plays: specialty materials (ATI, HAYN for HTS magnets), instrumentation.

LEU: At $205.59 vs 200MA $252 -- below 200MA. Enrichment demand rising but stock underperforming sector.

7. Battery Technology and Energy Storage -- MONITOR

• CATL/HyperStrong: 60 GWh sodium-ion battery deal (world's largest). Sodium-ion hitting commercial scale. 30-40% cost advantage over LFP at scale.
• Data center battery deployments accelerating (Caterpillar, GE Vernova).
• AMPX: $35M drone battery order, $10.5M DIU award, NDAA compliance positioning. Revenue guidance $125M+ for 2026, 25%+ gross margins. Stock at $19.69 (near ATH $22.80), well above 200MA $11.72.

8. Drones and Autonomous Systems -- HOT

• ONDS: Completed Mistral merger ($175M, adds $264M backlog). World View acquisition completed April 1. Pro forma backlog $457M. $10M Israel border security order. ONBERG JV in Germany. Stock +16% April, best month of 2026. At $10.48 vs 200MA $8.09.
• Red Cat (RCAT): Blue Ops/HADDY AI robotic production partnership to double manufacturing capacity.
• Shield AI: New investment interest, US Navy V-BAT program.
• KTOS: CCA drone wingman engine contracts (USAF). At $61.66 vs 200MA $80.72 -- below 200MA.
• Drones-as-a-Service market projected $550B by 2034.

9. Robotics and Industrial Automation -- MONITOR

• Flex/Teradyne Robotics partnership expansion for intelligent automation (April 22).
• Agile Robots/Google DeepMind: Gemini Robotics integration into 20K+ deployed systems.
• Generalist AI: GEN-1 robotics model with 99% success rates.
• NVIDIA Isaac for Healthcare: surgical robotics.
• NOVT: At $128.98, near 50MA $127.57. Q4 bookings +25%, book-to-bill 1.11x. Earnings May 12. Moderate positioning.
• CEVA: +15% April 24 on "ARM of NPUs" vision. Q1 earnings May 11. At $24.84 vs 200MA $22.95.

10. Military and Defense Technology -- MONITOR

• KTOS: CCA engine contracts for drone wingmen. At $61.66 but well below 200MA $80.72 and 52w high $134.
• Premier Graphene: First defense contract (Mexico).
• Castelion: Blackbeard hypersonic weapon Phase III testing.
• Virewirx: $1.9M SBIR for 5G in contested RF environments.
• No breakout catalyst in last 7 days for tracked tickers.

11. Peptides, Longevity, and Biohacking -- SKIP

• Unnatural Products: $45M Series B + $1.7B Novartis collaboration (macrocyclic peptides). Private.
• FDA reclassifying peptides in compounding guidelines.
• No liquid public play with fresh catalyst. Skip: no public play.

12. Cancer Treatments and Immunotherapy -- HOT

• RVMD: Phase 3 daraxonrasib data -- 13.2 months OS vs 6.7 months chemo in pancreatic cancer. ASCO Plenary Session. Evercore PT raised to $200, Guggenheim to $175. $2.23B raised ($1.5B equity + $500M converts). Stock from <$100 to $145 in April. Near ATH $155.70.
• NVCR: FDA approved Optune Pax for pancreatic cancer. PANOVA-4 Phase 2 met primary endpoint. Japan reimbursement approved. Earnings April 30. At $12.12, near 200MA $12.59. 6 analysts, Buy consensus.
• CD40 agonist direct tumor injection: 50% response rate (6/12 patients), 2 complete remissions in metastatic cancer (early trial).
• Zeaxanthin: Enhanced immunotherapy response in mouse models.

13. Novel Medicines and Drug Delivery -- MONITOR

• Peptide-loaded nanoparticles: 10x improvement in brain penetration (preclinical).
• Oregon State: Dual peptide nanoparticles crossing BBB for cancer cachexia.
• No liquid public play with near-term catalyst. Skip for daily actionability.

Phase 4.7: Momentum Leader Analysis

LITE (Lumentum) -- Structural Re-Rate

• Price vs 200MA: $791 / $367 = 2.16x (stretched but valid with catalysts)
• Catalyst density (3/3): JPMorgan PT $950, Northland PT $1,000, NVIDIA $2B investment, NC factory -- 4+ catalysts in April
• Catalyst type quality (3/3): Fundamental (NVIDIA strategic investment, capacity build, 90% revenue growth)
• Price vs 200MA (1/2): 2.16x (stretched)
• Narrative recognition (1/2): Analysts raising PTs but consensus still catching up to reality
• Score: 8/10 -- Momentum Leader, Add on Dips

COHR (Coherent) -- Structural Re-Rate

• Price vs 200MA: $304 / $175 = 1.74x
• Catalyst density (2/3): NVIDIA $2B investment, TD Cowen Buy initiation
• Catalyst type quality (3/3): Fundamental (NVIDIA strategic partnership, industrial laser recovery)
• Price vs 200MA (2/2): 1.74x (healthy re-rate zone)
• Narrative recognition (1/2): Consensus PT $253 still far below stock price
• Score: 8/10 -- Momentum Leader, Add on Dips

AAOI (Applied Optoelectronics) -- Structural Re-Rate

• Price vs 200MA: $137 / $49 = 2.80x (stretched)
• Catalyst density (3/3): $71M hyperscaler order, $124M total since March, 350% capacity expansion
• Catalyst type quality (3/3): Fundamental (customer orders, capacity expansion, US manufacturing)
• Price vs 200MA (1/2): 2.80x (stretched but still sub-3x)
• Narrative recognition (1/2): Rosenblatt PT $140 near current price -- partially recognized
• Score: 8/10 -- Momentum Leader, Add on Dips (but note earnings May 7 risk)

TSEM (Tower Semiconductor) -- Structural Re-Rate

• Price vs 200MA: $194 / $107 = 1.81x
• Catalyst density (2/3): 400 Gbps SiPh demo, Axiro SiGe IC ramp
• Catalyst type quality (3/3): Fundamental (SiPh production capability, defense IC ramp)
• Price vs 200MA (2/2): 1.81x (healthy re-rate zone)
• Narrative recognition (2/2): Still underfollowed despite multi-bagger move
• Score: 9/10 -- Momentum Leader, Add on Dips

AEHR (Aehr Test Systems) -- Structural Re-Rate

• Price vs 200MA: $82 / $31 = 2.65x (stretched)
• Catalyst density (3/3): Record $41M order, SiPh customer win, $92M+ H2 bookings
• Catalyst type quality (3/3): Fundamental (record orders, new end market in SiPh)
• Price vs 200MA (0/2): 2.65x (approaching 3x)
• Narrative recognition (1/2): Starting to get coverage but still small cap
• Score: 7/10 -- Momentum Leader, Add on Dips (extended, wait for pullback)

AXTI (AXT Inc) -- Structural Re-Rate with Red Flags

• Price vs 200MA: $69 / $20 = 3.39x (parabolic)
• Catalyst density (2/3): $632M offering closed, InP capacity expansion
• Catalyst type quality (2/3): Mixed (capital raise for expansion is positive but dilutive; revenue actually declined in FY25)
• Price vs 200MA (0/2): 3.39x (parabolic exhaustion zone)
• Narrative recognition (0/2): Fully recognized -- "6,000% AI stock" coverage everywhere
• Score: 4/10 -- Momentum Leader, Exhausted (valuation disconnected from current financials)

RVMD (Revolution Medicines) -- Structural Re-Rate

• Price vs 200MA: $145 / $75 = 1.93x
• Catalyst density (3/3): Phase 3 OS data (13.2 vs 6.7 mo), ASCO Plenary, $2.23B capital raise, Evercore PT $200
• Catalyst type quality (3/3): Fundamental (Phase 3 data is highest quality pharmaceutical catalyst)
• Price vs 200MA (2/2): 1.93x (healthy re-rate zone)
• Narrative recognition (1/2): Analysts upgrading but consensus still below price
• Score: 9/10 -- Momentum Leader, Add on Dips

ONDS (Ondas) -- Structural Re-Rate

• Price vs 200MA: $10.48 / $8.09 = 1.30x
• Catalyst density (3/3): Mistral merger completed, World View acquisition, Israel border order, ONBERG JV
• Catalyst type quality (3/3): Fundamental (backlog growth to $457M, defense prime access)
• Price vs 200MA (2/2): 1.30x (early re-rate, plenty of room)
• Narrative recognition (2/2): Very underfollowed relative to backlog transformation
• Score: 10/10 -- Momentum Leader, Add on Dips (highest conviction given backlog/cap ratio)

AMPX (Amprius) -- Structural Re-Rate

• Price vs 200MA: $19.69 / $11.72 = 1.68x
• Catalyst density (2/3): $35M drone order, NDAA compliance positioning
• Catalyst type quality (3/3): Fundamental (production orders, defense qualification)
• Price vs 200MA (2/2): 1.68x (healthy re-rate zone)
• Narrative recognition (2/2): Growing coverage but still underfollowed for defense battery moat
• Score: 9/10 -- Momentum Leader, Add on Dips

MU (Micron) -- Structural Re-Rate

• Price vs 200MA: $504 / $271 = 1.86x
• Catalyst density (3/3): HBM4 100% sold out, record quarterly revenue $23.86B, 74.4% gross margin
• Catalyst type quality (3/3): Fundamental (HBM4 volume production, capacity sold out)
• Price vs 200MA (2/2): 1.86x (healthy)
• Narrative recognition (0/2): 38 analysts, fully covered, consensus Strong Buy
• Score: 8/10 -- Momentum Leader, Add on Dips (but low info asymmetry)

AMKR (Amkor) -- Structural Re-Rate

• Price vs 200MA: $71 / $39 = 1.84x
• Catalyst density (2/3): Record Q1, 50% EPS beat, CPU packaging ramp H2
• Catalyst type quality (3/3): Fundamental (record revenue, advanced packaging ramp)
• Price vs 200MA (2/2): 1.84x (healthy)
• Narrative recognition (1/2): Consensus Hold at $55 -- massive disconnect to current price
• Score: 8/10 -- Momentum Leader, Add on Dips

Phase 4.5: Supply Chain Derivative Analysis

SiPh Supercycle Supply Chain

Drone/Autonomous Supply Chain

Nuclear Supply Chain (CFS Fusion Filing Catalyst)

Rare Earth / Sulfuric Acid Ban (T-2, May 1)

Oncology Supply Chain

Bottleneck Analysis

InP Substrate Bottleneck (CRITICAL)

• Global InP demand: 2M units in 2025; production capacity: 600K units (70% gap)
• Only 2-3 companies produce at scale (AXT/Tongmei, Sumitomo control ~75%)
• Orders fully booked through 2026
• Geopolitical risk: meaningful share of production touches China + Taiwan epitaxy concentration
• AXTI $632M raise is the market's response to this bottleneck
• But AXTI revenue declined in FY25 and stock is at 3.4x 200MA -- parabolic exhaustion risk
• Beneficiaries: AXTI (if it can execute), LITE/COHR (locked in supply), alternative substrate companies

Sulfuric Acid (T-2)

• China halting exports May 1, 2026
• Affects copper extraction (Chile, Congo, Zambia), fertilizer production (60% of global use), uranium leaching
• Spot prices already surging in Asia
• Beneficiaries: MP Materials (domestic RE processing avoids Chinese chemical dependency), LEU (uranium leaching alternative supply chains)

Asymmetric Entry Opportunities (Beaten-Down + Catalyst)

NVCR -- NovoCure ($12.12)

• Near 200MA ($12.59), well below 52w high ($20.06)
• Catalyst stack: FDA Optune Pax approval, PANOVA-4 data positive, Japan reimbursement, earnings April 30
• Revenue growing 8% YoY to $655M, approaching breakeven
• 6 analysts, Buy consensus
• Risk: Commercial execution of pancreatic indication
• Score: 7/10 | Timing: Now (earnings catalyst Apr 30)

LEU -- Centrus Energy ($205.59)

• Below 200MA ($252.32), well below 52w high ($464)
• DOE loan confirmation for first 5-10 reactors is structural
• Only US-licensed HALEU enrichment capability
• Space nuclear initiative adds new demand vector
• Legal/political risk around enrichment
• Score: 6/10 | Timing: Watch (wait for nuclear policy clarity)

OKLO ($69.09)

• Below 200MA ($86.22), well below 52w high ($193.84)
• DOE loan catalyst + NVIDIA partnership + HSBC Buy/$96 PT
• Pre-revenue, speculative -- 14 GW in non-binding LOIs
• Score: 5/10 | Timing: Watch (pre-revenue, speculative)

KTOS -- Kratos ($61.66)

• Below 200MA ($80.72), well below 52w high ($134)
• CCA drone wingman engine contracts (USAF)
• No fresh company-specific catalyst in last 7 days
• Score: 5/10 | Timing: Watch -- no fresh catalyst in last 7 days

MP Materials ($61.70)

• Near 200MA ($62.83), well below 52w high ($100.25)
• Sulfuric acid ban T-2 is structural catalyst for onshoring
• Only US integrated RE mine+processor
• Score: 6/10 | Timing: Now (May 1 sulfuric acid ban imminent)

Key Risks and Red Flags

1. AXTI: Revenue declining while stock up 6,000%. $632M dilutive offering. Parabolic at 3.4x 200MA.
2. POET: -47% crash on Marvell order cancellation. Execution risk extreme. 20 years unprofitable.
3. CRDO: 84% customer concentration. Insider selling. Zacks downgrade.
4. NuScale (SMR): Securities fraud class action. -70% in 6 months.
5. RVMD: $2.23B capital raise is dilutive near-term. Premium valuation for pre-profit biotech.

Sources

• OFC 2026 Announcements
• NVIDIA $4B Photonics Investment
• InP Bottleneck Analysis
• CATL Sodium-Ion 60 GWh Deal
• CFS Grid Filing
• RVMD Daraxonrasib OS Data
• AEHR Record Order
• ONDS Mistral Merger
• LITE JPMorgan PT Raise
• China Sulfuric Acid Ban
• AXTI $632M Offering
• NVCR TTFields Pancreatic Data
• AMPX Drone Battery Orders